To confirm MiSL's prediction, we treated a panel of PIK3CA mutant (MCF-7, T47D, CAL-148, CAL-51) and PIK3CA wild-type (CAL-120, HCC-1806, HCC-38, SKBR-7) breast cancer cell lines with MK-2206 in 5-day cell viability assays (Fig. 4d) and colony-formation assays (Supplementary Fig. 5e). The gene discussed is PIK3CA; the disease is breast carcinoma.